Memorial Sloan Kettering Cancer Center

Roche's five-year follow-up of the POLARIX study shows Polivy (polatuzumab vedotin) in combination with R-CHP improves outcomes for untreated diffuse large B-cell lymphoma (DLBCL), with a positive trend in overall survival and reduced need for follow-up treatments. Polivy plus R-CHP is approved in over 90 countries and maintains benefits in progression-free and disease-free survival.

Carta Healthcare® acquired Realyze Intelligence to enhance its AI-powered platform, accelerating clinical trial research and reducing costs. The combined AI-driven solutions improve data abstraction, patient matching, and trial recruitment, aiming to transform healthcare practices and patient outcomes.

Epcoritamab (DuoBody® CD3xCD20) induces durable, complete responses in DLBCL patients, with ORR of 100% and CR rate of 87% in high-risk, previously untreated DLBCL patients in EPCORE® NHL-2 trial, and 59% ORR and 41% CR rate in R/R LBCL patients in EPCORE® NHL-1 trial, both presented at ASH 2024.

DLBCL, the most common NHL, affects 25-30% of NHL cases globally, with 25,000 new U.S. cases annually. DLBCL, a fast-growing NHL, often relapses or becomes refractory despite new therapies. Epcoritamab studies show promise in Phase 3 trials, with 91% MRD negativity in high-risk DLBCL patients and 59% ORR in R/R LBCL patients, highlighting potential for durable responses.

AbbVie announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody, in adult patients with diffuse large B-cell lymphoma (DLBCL) at the 66th ASH Annual Meeting. The Phase 1b/2 EPCORE NHL-2 trial showed an overall response rate (ORR) of 100% and a complete response (CR) rate of 87% in high-risk DLBCL patients. The Phase 2 EPCORE NHL-1 trial, evaluating epcoritamab monotherapy in relapsed or refractory large B-cell lymphoma (LBCL) patients, showed a CR rate of 41% with an estimated 52% still responding at three years.

Dr. C. Ola Landgren's research led to FDA approval of minimal residual disease (MRD) as an endpoint for accelerated drug approval in multiple myeloma, potentially cutting a decade off the drug development process.

A City of Hope study suggests a high-fiber diet may reduce graft-versus-host disease (GVHD) and myeloma risk in blood cancer patients post bone marrow/stem cell transplant, improving overall survival. High fiber intake was linked to reduced acute GVHD risk, better gut microbiome diversity, and higher butyrate levels, as shown in both human and mouse models.

Carta Healthcare® acquired Realyze Intelligence to enhance its AI-powered platform, accelerating clinical trial research and reducing costs. The combined AI-driven solutions improve data abstraction efficiency and patient outcomes, particularly in oncology, by leveraging clinician-trained AI and human oversight.